Brutons tyrosine kinase SH2 inhibitor (Recludix Pharma)

N/A

Report date: 2025/06/03 15:46:08
NMEFirst In Class

Base Information

Drug NameBrutons tyrosine kinase SH2 inhibitor (Recludix Pharma)
Drug Alias NameBTK-SH2i
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBTK SH2 Domain Inhibitor
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsChronic Urticaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRecludix Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesRecludix Pharma Inc
Inactive CompaniesN/A
Active IndicationsChronic Urticaria
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A